In Reply by Goldstein, A.O.
permission for postmortem examina¬
tions when an unanticipated and seem¬
ingly inexplicable death of a patient oc¬
curs? Regrettably, national statistics
would seem to indicate that this is exact¬
ly what is happening.
Cyril Wecht, MD, JD
Pittsburgh, Pa
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In Reply. \p=m-\Thepurpose ofmy essay was
to expose the personal shortcomings in
the way our society chooses to handle
medical malpractice lawsuits. Such
shortcomings manifest themselves for
physicians in at least two ways. First,
most clinicians, regardless of their spe-
cialty or the health care setting, at least
think about potential malpractice law-
suits subconsciously and consciously,
and probably on at least a weekly if not
daily basis, regardless of whether they
have personally ever been sued. An aura
of silence usually surrounds such
thoughts despite the enormous implica-
tions for patient care. Second, as clini-
cians, we somehow often feel immune to
the same diseases attacking the immune
systems of our patients: stress, anger,
hostility, rejection, burnout, disap-
pointment, and more. Medical malprac-
tice lawsuits, regardless of their origin,
pathophysiology, or prognosis, nega-
tively affect our personal and our fam-
ily's health. Our own self-healing pro-
cess can begin by openly acknowledging
and discussing such effects, rather than
acquiescing to silence, shame, or guilt.
In his letter, Wecht bemoans the fact
that "the percentage ofhospital and oth¬
er private autopsies continues to de¬
cline," attempting to link such declines
to the high rates of medical malpractice
lawsuits. I do not know of any research
that establishes such a relationship.
Wecht is correct to reinforce the impor¬
tance of autopsies as an important part
ofmedical education, research, and clin¬
ical care, but his assumptions that I was
sued after a patient under my care died
unexpectedly before planned discharge
from the hospital and that I did not seek
an autopsy in the case, implying that
such autopsy was actually purposefully
avoided, are both false. The patient's
family explicitly refused multiple re¬
quests for an autopsy. My interest in the
autopsy was to learn from the cause of
death so that I could take better care of
patients in the future.
Physicians should not be asked to or¬
der autopsies to defend their own inter¬
ests. While autopsies certainly may be
used to justify a physician's actions in a
medical malpractice lawsuit, it is a fact
that the outcomes of such autopsies are
also used to initiate these lawsuits. ' The
true purpose for autopsies would ap¬
pear to lie in the advancement of seien-
tifie knowledge and assistance in crimi¬
nal investigations. Avoiding medical
malpractice lawsuits is more easily ac¬
complished by long-term, trusting phy¬
sician-patient relationships. Such rela¬
tionships are difficult to establish post
mortem.
Adam O. Goldstein, MD
Chapel Hill, NC
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To the Editor.\p=m-\Vlahovet al1 recently
found higher human immunodeficiency
virus type 1 (HIV-1) seroprevalence
among female than male inmates in nine
of 10 US correctional facilities sur-
veyed. Seroprevalence among younger
women (<26 years) was higher than
among younger men but similar to that
in both older women and older men. In
their blinded study, Vlahov et al were
unable to evaluate the extent to which
female inmates were more likely to be
intravenous drug users and to have ac-
quired HIV-1 infection through paren-
teral transmission.
We reviewed the results of an anony-
mous 1987 survey of 3037 inmates in the
Cook County (Illinois) Department of
Corrections in order to determine if fe-
male inmates were more likely than
male inmates to have a history of inject-
able drug use. In stratified analyses ad-
justed for differences in race-ethnicity
and age, female inmates were almost
twice as likely as male inmates to report
injectable drug use (adjusted odds ratio
[OR] = 1.92; 95% confidence interval,
1.50 to 2.46). Moreover, the greater
likelihood of female inmates to report a
lifetime history of injectable drug use
was significantly and inversely associ¬
ated with age; ORs ranged from 2.13
among inmates younger than 26 years to
1.22 among inmates older than 45 years
(Mantel extension for the test of trend:
2 = 25.27,1 of; P<. 001).
These results and those of Vlahov et
al may reflect gender- and age-related
differences in the reason for incarcera¬
tion. Both studies support the view that
incarcerated younger women are likely
to be HIV-1 seropositive due to intrave¬
nous drug use.
We believe it is important to under¬
score the potential of correctional facili¬
ties for reaching younger intravenous
drug users, both male and female. In
our survey, 17% of those who reported
prior drug use with a needle were youn¬
ger than 25 years. These recent initiates
to intravenous drug use are at a high
risk for HIV-1 infection2 s but are unlike¬
ly to seek drug abuse treatment for sev-
eral years.4 Correctional facilities pro¬
vide a setting for HIV-1 surveillance
activities and the provision of acquired
immunodeficiency syndrome-risk re¬
duction counseling to younger intrave¬
nous drug users.
Thomas M. Lampinen
University of Illinois at Chicago
School ofPublic Health
Arthur M. Brewer, MD
John M. Raba, MD
Cermak Health Services
Cook County Department ofCorrections
Chicago, III
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Seasonality in Sudden Infant
Death Syndrome
To the Editor.\p=m-\\p=m-\Amajor objective of
the Centers for Disease Control (CDC)
Mortality and Morbidity Weekly Re-
port is to document disease trends accu-
rately. The effort to achieve this goal in
the CDC study on sudden infant death
and seasonality1 was weakened by a fail-
ure to exclude cases certified as sudden
infant death syndrome (SIDS) in which
a death-scene investigation was not per-
formed. Contrary to common belief, a
high autopsy rate in a SIDS study con-
firmed by death certificate data does not
strengthen the validity of this study
when information is lacking concerning
death-scene investigation of the pre-
sumed SIDS cases.2,3
The observation by the author of the
CDC report that the risk of SIDS was
greatest for those white male infants
whose mothers resided in the western
United States must be cautiously inter-
preted since nonwhite Hispanic infants
may be classified as white on death cer-
tificates. Because the incidence of SIDS
is higher in Hispanic, black, and Native
American populations, and because the
largest and fastest growing Hispanic
population is in the West, the emerging
SIDS trend in white male infants, as
suggested by the CDC, may represent
SIDS cases from Hispanic minority
groups that were misclassified accord¬
ing to race or ethnicity in the early and
middle 1980s. During the last few years,
governmental agencies responsible for
vital statistics have encouraged more
